ZIKA VIRUS NS1 PROTEIN (UGANDA STRAIN)

Zika virus NS1 protein 1 (Non-Structural protein 1) has been manufactured in response to the unmet need for highly purified, concentrated protein for use in serological based diagnostic assays. Zika virus NS1 protein is engineered in human cells using state-of-the-art expression and purification techniques. Zika virus NS1 has been produced to the same standards as other NS1 proteins, and is presented as a highly purified liquid protein.

PRODUCT DETAILS – ZIKA VIRUS NS1 PROTEIN (UGANDA STRAIN)

• Recombinant Zika virus NS1 protein (strain Uganda MR766, NCBI Accession Number: AWF93629.1).
• Includes amino acids 791-1142 of the polyprotein and a C-terminal His-tag.
• Buffered in DPBS, pH7.4.

BACKGROUND

Zika virus is an emerging disease that is spread by Aedes mosquitoes. The virus was first isolated in Central Africa, and has since been spread to South Asia and recently to South America. Outbreaks were reported in Micronesia in 2007 and in Brazil in 2015, confirming at least 13 autochthonous infections.The Zika virus outbreak in Brazil in 2016 has gained world-wide attention, and has been linked to an increasing number of microcephaly cases. In April 2016 the Centers for Disease Control, in the USA, confirmed the link between Zika virus infection of the fetus with microcephaly.

Zika virus can cause mild fever, rash, myalgia, arthralgia and headaches, with one in four infected individuals being asymptomatic. Due to similar symptoms Zika virus infected individuals can easily be mis-diagnosed as a dengue infection and vice-versa. In addition, Zika virus has been implicated in causing microcephaly through transmission in utero. There is no vaccine or specific treatment available for Zika virus.

Analysis of Zika virus sequences from infected patients have shown that the strain circulating in South America in 2015 differs to the strain originally isoloated in 1947 in Uganda (the “Uganda” strain). The South American strain was first isolated and sequenced from a patient in Suriname, and hence is known as the Zika Suriname strain. 7. The Native Antigen Company are pleased to make available Zika Virus NS1 protein from both the Uganda and Suriname strains, enabling researchers to carefully study the differences between the two antigens and the host response to them.